File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Early detection of persistent trophoblastic tumour by serum human chorionic gonadotrophin monitoring after molar pregnancy

TitleEarly detection of persistent trophoblastic tumour by serum human chorionic gonadotrophin monitoring after molar pregnancy
Authors
Issue Date1999
PublisherChinese Medical Association. The Journal's web site is located at http://www.cmj.org/
Citation
Chinese Medical Journal, 1999, v. 112 n. 3, p. 260-263 How to Cite?
AbstractObjective: To study the outcome of a multi-centred post-molar pregnancy serum human chorionic gonadotrophin (hCG) surveillance programme. Methods: Patients recruited into the multi-centred post-molar serum hCG surveillance programme between 1988 and 1996 were studied. The clinical data were obtained from medical records and computer database. Results: There were 616 patients in the study. Twenty-five (11%) of 224 patients with molar pregnancy and 28 (7%) of 392 patients with partial molar pregnancy were diagnosed to have persistent trophoblastic tumour (PTT) requiring chemotherapy. Of the 53 patients treated for PTT, 58.5% received intravenous methotrexate (MTX), 22.6% received both MTX and actinomycin D, and 19% received CHAMOC, a multiple chemotherapeutic regimen. Four patients receiving single drug had to change the regimen because of poor response, and all recovered and remained well. There were 3 cases of recurrence, one in each group of patients receiving single, dual or multiple agents. One patient died because of treatment complication. The rest were well with a mean follow-up of 42 months. Conclusions: Post-molar serum hCG surveillance is important to detecting persistent trophoblastic activity. Early treatment of PTT by the appropriate chemotherapy has a near hundred percent cure and prevents the progression of PTT into more advanced trophoblastic malignancy such as choriocarcinoma.
Persistent Identifierhttp://hdl.handle.net/10722/173271
ISSN
2015 Impact Factor: 0.957
2015 SCImago Journal Rankings: 0.428
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorWong, LWen_US
dc.date.accessioned2012-10-30T06:28:58Z-
dc.date.available2012-10-30T06:28:58Z-
dc.date.issued1999en_US
dc.identifier.citationChinese Medical Journal, 1999, v. 112 n. 3, p. 260-263en_US
dc.identifier.issn0366-6999en_US
dc.identifier.urihttp://hdl.handle.net/10722/173271-
dc.description.abstractObjective: To study the outcome of a multi-centred post-molar pregnancy serum human chorionic gonadotrophin (hCG) surveillance programme. Methods: Patients recruited into the multi-centred post-molar serum hCG surveillance programme between 1988 and 1996 were studied. The clinical data were obtained from medical records and computer database. Results: There were 616 patients in the study. Twenty-five (11%) of 224 patients with molar pregnancy and 28 (7%) of 392 patients with partial molar pregnancy were diagnosed to have persistent trophoblastic tumour (PTT) requiring chemotherapy. Of the 53 patients treated for PTT, 58.5% received intravenous methotrexate (MTX), 22.6% received both MTX and actinomycin D, and 19% received CHAMOC, a multiple chemotherapeutic regimen. Four patients receiving single drug had to change the regimen because of poor response, and all recovered and remained well. There were 3 cases of recurrence, one in each group of patients receiving single, dual or multiple agents. One patient died because of treatment complication. The rest were well with a mean follow-up of 42 months. Conclusions: Post-molar serum hCG surveillance is important to detecting persistent trophoblastic activity. Early treatment of PTT by the appropriate chemotherapy has a near hundred percent cure and prevents the progression of PTT into more advanced trophoblastic malignancy such as choriocarcinoma.en_US
dc.languageengen_US
dc.publisherChinese Medical Association. The Journal's web site is located at http://www.cmj.org/en_US
dc.relation.ispartofChinese Medical Journalen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntibiotics, Antineoplastic - Therapeutic Useen_US
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshChorionic Gonadotropin - Blooden_US
dc.subject.meshDactinomycin - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHydatidiform Mole - Blooden_US
dc.subject.meshMethotrexate - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPregnancyen_US
dc.subject.meshTrophoblastic Neoplasms - Blood - Diagnosis - Drug Therapyen_US
dc.subject.meshUterine Neoplasms - Blood - Diagnosis - Drug Therapyen_US
dc.titleEarly detection of persistent trophoblastic tumour by serum human chorionic gonadotrophin monitoring after molar pregnancyen_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid11593563-
dc.identifier.scopuseid_2-s2.0-0345040633en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0345040633&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume112en_US
dc.identifier.issue3en_US
dc.identifier.spage260en_US
dc.identifier.epage263en_US
dc.identifier.isiWOS:000079139900017-
dc.publisher.placeChinaen_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridWong, LW=36947357000en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats